Teva Pharmaceutical Industries Sees Unusually Large Options Volume (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw some unusual options trading activity on Wednesday. Stock investors acquired 170,268 call options on the company. This is an increase of 417% compared to the typical volume of 32,957 call options.

Wall Street Analyst Weigh In

Several research firms have issued reports on TEVA. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Bank of America boosted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, May 8th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Finally, Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $24.43.

Teva Pharmaceutical Industries Trading Down 1.2%

Shares of TEVA stock opened at $16.58 on Thursday. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $22.80. The stock has a market cap of $18.79 billion, a price-to-earnings ratio of -11.43, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a fifty day moving average of $15.37 and a 200-day moving average of $17.38.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. During the same quarter in the prior year, the company posted $0.48 EPS. The business’s revenue was up 1.9% on a year-over-year basis. On average, equities research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in TEVA. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company’s stock valued at $338,989,000 after purchasing an additional 22,044,407 shares during the last quarter. FMR LLC raised its holdings in Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after buying an additional 19,242,468 shares during the period. Duquesne Family Office LLC raised its holdings in shares of Teva Pharmaceutical Industries by 530.1% in the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company’s stock valued at $198,303,000 after purchasing an additional 7,569,450 shares during the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Teva Pharmaceutical Industries by 472.8% in the first quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company’s stock valued at $96,078,000 after purchasing an additional 5,186,592 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in shares of Teva Pharmaceutical Industries by 416.0% in the first quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company’s stock valued at $91,973,000 after buying an additional 4,824,247 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.